Scientific Publication


 
    Dengue: Nucleocytoplasmic Trafficking of Dengue Non-structural Protein 5 as a Target for Antivirals  

Signal-dependent movement of proteins into and out of the nucleus through the importin superfamily of transporters is central to the replication of many viruses in infected cells, including RNA viruses such as the flavivirus Dengue virus (DENV).

  • David A. Jans
  • Alexander J. Martin
 
    Zika: Nuclear import inhibitor N-(4-hydroxyphenyl) retinamide targets Zika virus (ZIKV) nonstructural protein 5 to inhibit ZIKV infection  

In the absence of approved therapeutics, Zika virus (ZIKV)'s recent prolific outbreaks in the Americas, together with impacts on unborn fetuses of infected mothers, make it a pressing human health concern worldwide. Although a key player in viral replication in the infected host cell cytoplasm, ZIKV non-structural protein 5 (NS5) appears to contribute integrally to pathogenesis by localising in the host cell nucleus, in a similar fashion to NS5 from Dengue virus (DENV).

  • Chunxiao Wang
  • Sundy N Y Yang
  • Kate Smith
  • Jade K Forwood
  • David A Jans
 
    Zika: Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus  

The rapid spread of Zika virus (ZIKV) in recent years has highlighted the severe diseases associated with ZIKV infection, such as Guillain-Barré syndrome in adults and microcephaly in newborns; yet no vaccines or antivirals currently exist to prevent or treat ZIKV infection.

  • Jared D Pitts
  • Pi-Chun Li
  • Melissanne de Wispelaere
  • Priscilla L Yang
 
    Dengue: The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication  

Dengue virus (DENV), a member of the Flaviviridae family, is a mosquito-borne pathogen and the cause of dengue fever. The increasing prevalence of DENV worldwide heightens the need for an effective vaccine and specific antivirals. 

 
    Dengue: A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection  

Dengue virus (DENV) is estimated to cause 390 million infections each year, but there is no licensed vaccine or therapeutic currently available.